ChiCTR2400088053 版本V1.0 版本创建时间2024/08/09 15:09:57 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2400088053 

最近更新日期:

Date of Last Refreshed on:

2024-08-09 15:09:52 

注册时间:

Date of Registration:

2024-08-09 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

口腔鳞癌营养-炎症负荷评价体系与预后预测模型建立的双向队列研究

Public title:

A Bidirectional Cohort Study on the Establishment of a Nutrition-Inflammation Burden Assessment System and Prognostic Prediction Model for Oral Squamous Cell Carcinoma

注册题目简写:

English Acronym:

研究课题的正式科学名称:

口腔鳞癌营养-炎症负荷评价体系与预后预测模型建立的双向队列研究

Scientific title:

A Bidirectional Cohort Study on the Establishment of a Nutrition-Inflammation Burden Assessment System and Prognostic Prediction Model for Oral Squamous Cell Carcinoma

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

王翀 

研究负责人:

王翀 

Applicant:

Wang Chong 

Study leader:

Wang Chong 

申请注册联系人电话:

Applicant telephone:

+86 138 1026 1903

研究负责人电话:

Study leader's
telephone:

+86 138 1026 1903

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

375530313@qq.com

研究负责人电子邮件:

Study leader's E-mail:

375530313@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

北京市东城区天坛西里4号

研究负责人通讯地址:

北京市东城区天坛西里4号

Applicant address:

No.4 Tian Tan Xi Li, Dongcheng District, Beijing

Study leader's address:

No.4 Tian Tan Xi Li, Dongcheng District, Beijing

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

首都医科大学附属北京口腔医院

Applicant's institution:

Beijing Stomatological Hospital, Capital Medical University

研究负责人所在单位:

首都医科大学附属北京口腔医院

Affiliation of the Leader:

Beijing Stomatological Hospital, Capital Medical University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

CMUSH-IRB-KJ-PJ-2024-29

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

首都医科大学附属北京口腔医院伦理委员会

Name of the ethic committee:

Ethics Board of Beijing Stomatological Hospital, Capital Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2024-04-30 00:00:00

伦理委员会联系人:

夏晓钰

Contact Name of the ethic committee:

Xia Xiaoyu

伦理委员会联系地址:

北京市东城区天坛南里西区18号楼2单元307

Contact Address of the ethic committee:

307, Unit 2, Building 18, Tiantan Nanli West District, Dongcheng District, Beijing

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 10 5709 9307

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

首都医科大学附属北京口腔医院

Primary sponsor:

Beijing Stomatological Hospital, Capital Medical University

研究实施负责(组长)单位地址:

北京市东城区天坛西里4号

Primary sponsor's address:

No.4 Tian Tan Xi Li, Dongcheng District, Beijing

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京市

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

首都医科大学附属北京口腔医院

具体地址:

北京市东城区天坛西里4号

Institution
hospital:

Beijing Stomatological Hospital, Capital Medical University

Address:

No.4 Tian Tan Xi Li, Dongcheng District, Beijing

经费或物资来源:

首都医科大学附属北京口腔医院临床研究孵化项目

Source(s) of funding:

Clinical research incubation program of Beijing Stomatological Hospital, Capital Medical University

研究疾病:

口腔鳞状细胞癌  

Target disease:

oral squamous cell carcinoma

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

队列研究 

Study design:

Cohort study 

研究目的:

(1)采集口腔鳞癌患者基线临床资料及营养相关指标、炎症指标,建立口腔鳞癌回顾性营养-炎症数据库,验证GLIM标准在口腔鳞癌患者群体的适用性,确定营养不良、肥胖等异常营养状态的发生率; (2)构建口腔鳞癌围治疗期营养-炎症负荷的预后预测Nomogram模型; (3)完善更新口腔鳞癌前瞻性数据库,收集更加全面的营养、炎症负荷数据,验证Nomogram模型,指导临床评估口腔鳞癌营养状态及炎症状态,为口腔鳞癌精准化营养-炎症干预提供研究基础及循证医学证据。  

Objectives of Study:

(1) To collect baseline clinical data, nutrition-related indexes and inflammatory indicators of patients with oral squamous cell carcinoma, establish a retrospective nutrition-inflammation database of oral squamous cell carcinoma, verify the applicability of GLIM standards in oral squamous cell carcinoma patients, and determine the incidence of abnormal nutritional states such as malnutrition and obesity; (2) To construct a Nomogram model for predicting the prognosis of nutritional-inflammatory burden in the peritreatment period of oral squamous cell carcinoma; (3) To improve and update the prospective database of oral squamous cell carcinoma, collect more comprehensive nutritional and inflammatory burden data, validate the Nomogram model, guide the clinical evaluation of nutritional status and inflammatory status of oral squamous cell carcinoma, and provide research basis and evidence-based medical evidence for precise nutrition-inflammation intervention for oral squamous cell carcinoma.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

(1) 年龄:18岁以上(含18岁); (2) 性别:男女不限; (3) 原发首诊患者,术前或术后病理证实为鳞癌; (4) 肿瘤部位:唇、舌体、颊黏膜、上下牙龈(含磨牙后区)、口底、硬腭黏膜; (5) 临床分期:cT1-4N0-3M0(基于临床检查、增强CT/MRI); (6) 接受我院口腔癌根治性手术治疗;全身情况能耐受治疗方案,无手术禁忌证,通过X线胸片和/或腹部B超等排除远处转移,可疑者增强CT 和/或MRI 和/或PET/CT 检查辅助诊断。

Inclusion criteria

(1) Age: 18 years old or above (including 18 years old); (2) Gender: male or female; (3) The primary first-time patient, preoperative or postoperative pathologically confirmed to be squamous cell carcinoma; (4) Tumor site: lips, tongue, buccal mucosa, upper and lower gingiva (including posterior molars), floor of the mouth, hard palate mucosa; (5) Clinical stage: cT1-4N0-3M0 (based on clinical examination, contrast-enhanced CT/MRI); (6) Radical surgery for oral cancer in our hospital; The systemic condition can tolerate the treatment regimen, there are no contraindications to surgery, distant metastases are excluded by chest x-ray and/or abdominal ultrasound, and CT and/or MRI and/or PET/CT with contrast in suspicious cases to assist in diagnosis.

排除标准:

(1) 临床病例资料无法获取; (2) 营养/炎症负荷关键变量值缺失; (3) 妊娠或哺乳期妇女; (4) 患有精神障碍或智力障碍预计无法完成治疗及随访。

Exclusion criteria:

(1) Clinical case data cannot be obtained; (2) Missing values of key variables of nutrient/inflammatory burden; (3) pregnant or lactating women; (4) Those with mental disorder or intellectual disability are expected to be unable to complete treatment and follow-up.

研究实施时间:

Study execute time:

From 2024-05-01 00:00:00 To 2026-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2024-08-09 00:00:00 To 2025-12-31 00:00:00

干预措施:

Interventions:

组别:

前瞻性队列

样本量:

230

Group:

prospective cohort

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

组别:

回顾性队列

样本量:

345

Group:

retrospective cohort

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

北京市 

市(区县):

 

Country:

China

Province:

Beijing

City:

单位(医院):

首都医科大学附属北京口腔医院 

单位级别:

三甲 

Institution
hospital:

Beijing Stomatological Hospital, Capital Medical University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

术后3年疾病特异性生存率

指标类型:

主要指标

Outcome:

3-year Disease-specific survival rate

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

总生存期

指标类型:

次要指标

Outcome:

Over-all survival

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

无病生存期

指标类型:

次要指标

Outcome:

Disease-free survival

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

术后并发症发生率

指标类型:

次要指标

Outcome:

incidence of postoperative complications

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

none

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age NA years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

由临床研究人员对符合纳排标准的已连续入组的受试者编号

Randomization Procedure (please state who generates the random number sequence and by what method):

Consecutively enrolled subjects meeting the inclusion criteria were numbered by the clinical investigator

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

None

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

None

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

本研究设有试验记录本及病例报告表,在试验记录本上记录本研究中试验过程和试验结果,病例报告表记录患者临床病理信息、随访周期和随访内容。所有数据将由课题负责人及时、真实、准确、完整的记录在试验记录本和病例报告表内,并由课题负责人负责管理。 电子数据文件,如:数据库、检查程序、分析程序、分析结果、编码本和说明文件等,将分类保存,双备份保存于不同磁盘或记录介质上,妥善保存,防止损坏。项目结题后继续保存两年,两年后及时销毁,彻底删除相关数据资料。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

This study has a trial record book and a case report form, in which the trial process and test results in the study are recorded, and the case report form records the patient's clinicopathological information, follow-up cycle and follow-up content. All data will be recorded in the trial record book and case report form in a timely, true, accurate and complete manner by the project leader, and will be managed by the project leader. Electronic data files, such as databases, inspection programs, analysis programs, analysis results, coded books and instruction files, etc., will be stored in a classified manner, and the double backup will be stored on different disks or recording media to prevent damage. After the project is completed, it will continue to be stored for two years, and it will be destroyed in time after two years, and the relevant data will be completely deleted.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2024-08-09 15:09:52